Esperion Therapeutics, Inc. — Director's Dealing 2017

Dec 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2017-12-18

Reporting Person: GOLDSTEIN DOV A MD (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-18	Common Stock	M	21471	$3.70	Acquired	21518	Direct
2017-12-18	Common Stock	J	21471	$0.00	Disposed	47	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-18	Stock Option (right to buy)	$3.70	M	21471	Disposed	2023-04-11	Common Stock (21471)	Direct

Footnotes

F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein.